

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2024/2025 influenza season

as of April 14, 2026

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	3 (0.3%)	21 (1.0%)	21 (1.0%)	0	0	349 (100%)	2 (0.8%)	0	0	0	0	186 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	861	2,134	2,134	343	343	349	260	186	186	186	186	186	195	156	156	156	156
<b>Number of viruses reported</b>	3,926						671						667				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.